(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
15 July 2004 (15.07.2004)

PCT

(10) International Publication Number
WO 2004/058753 A1

(51) International Patent Classification[7]: C07D 417/12, 417/14, 413/12, 413/14, 473/38, 495/04, A61K 31/4709, 31/52, 31/517, 31/519, A61P 37/00

(21) International Application Number:
PCT/US2003/014223

(22) International Filing Date: 6 May 2003 (06.05.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/378,185 6 May 2002 (06.05.2002) US

(71) Applicant *(for all designated States except US)*: **VERTEX PHARMACEUTIVALS INCORPORATED** [US/US]; 130 Waverly Street, Cambridge, MA 02139 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **BEMIS, Guy, W.** [US/US]; 256 Appleton Street, Arlington, MA 02476 (US). **HARBESON, Scott, L.** [US/US]; 203 Pemberton St., Apt. 5, Cambridge, MA 02140 (US). **LEDEBOER, Mark** [US/US]; 36 Faulkner Hill Road, Acton, MA 01720 (US).

(74) Agent: **SHAIR, Karoline, K.M.**; Vertex Pharmaceuticals Incorporated, 130 Waverly Street, Cambridge, MA 02139 (US).

(81) Designated States *(national)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.


(84) Designated States *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 2004/058753 A1

(54) Title: THIADIAZOLES OR OXADIAZOLES AND THEIR USE AS INHIBITORS OF JAK PROTEIN KINASE



(I)

(57) Abstract: The present invention relates to compounds of formula (I), or a pharmaceutically acceptable salt thereof, wherein: W and X are each independently oxygen or sulfur; A is nitrogen, CH, C-CN, or C-(C_{1-3} aliphatic); and R^1 and R^2 are taken together to form a ring. These compounds are useful as inhibitors or JAK kinases, particularly for the treatment of an autoimmune disease, a neurodegenerative disorder, or a hematologic malignancy.